DE20321889U1 - Impfstoffzusammensetzung - Google Patents

Impfstoffzusammensetzung Download PDF

Info

Publication number
DE20321889U1
DE20321889U1 DE20321889U DE20321889U DE20321889U1 DE 20321889 U1 DE20321889 U1 DE 20321889U1 DE 20321889 U DE20321889 U DE 20321889U DE 20321889 U DE20321889 U DE 20321889U DE 20321889 U1 DE20321889 U1 DE 20321889U1
Authority
DE
Germany
Prior art keywords
neisseria
hsf
tbpa
protein
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE20321889U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31722002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE20321889(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0218051A external-priority patent/GB0218051D0/en
Priority claimed from GB0218036A external-priority patent/GB0218036D0/en
Priority claimed from GB0218035A external-priority patent/GB0218035D0/en
Priority claimed from GB0218037A external-priority patent/GB0218037D0/en
Priority claimed from GBGB0220199.4A external-priority patent/GB0220199D0/en
Priority claimed from GBGB0220197.8A external-priority patent/GB0220197D0/en
Priority claimed from GB0225524A external-priority patent/GB0225524D0/en
Priority claimed from GB0225531A external-priority patent/GB0225531D0/en
Priority claimed from GB0230164A external-priority patent/GB0230164D0/en
Priority claimed from GB0230168A external-priority patent/GB0230168D0/en
Priority claimed from GB0230170A external-priority patent/GB0230170D0/en
Priority claimed from GB0305028A external-priority patent/GB0305028D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE20321889U1 publication Critical patent/DE20321889U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE20321889U 2002-08-02 2003-07-31 Impfstoffzusammensetzung Expired - Lifetime DE20321889U1 (de)

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
GB0218051A GB0218051D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218035.4 2002-08-02
GB0218037.0 2002-08-02
GB0218036.2 2002-08-02
GB0218036A GB0218036D0 (en) 2002-08-02 2002-08-02 Vaccine
GB0218051.1 2002-08-02
GB0218035A GB0218035D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218037A GB0218037D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
GB0220199.4 2002-08-30
GB0220197.8 2002-08-30
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
GB0225524A GB0225524D0 (en) 2002-11-01 2002-11-01 Vaccine composition
GB0225531.3 2002-11-01
GB0225531A GB0225531D0 (en) 2002-11-01 2002-11-01 Vaccine
GB0225524.8 2002-11-01
GB0030170.3 2002-12-24
GB0230164.6 2002-12-24
GB0230168.7 2002-12-24
GB0230164A GB0230164D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230168A GB0230168D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230170A GB0230170D0 (en) 2002-12-24 2002-12-24 Vaccine
GB0305028A GB0305028D0 (en) 2003-03-05 2003-03-05 Vaccine
GB0005028.3 2003-03-05

Publications (1)

Publication Number Publication Date
DE20321889U1 true DE20321889U1 (de) 2012-03-12

Family

ID=31722002

Family Applications (2)

Application Number Title Priority Date Filing Date
DE20321889U Expired - Lifetime DE20321889U1 (de) 2002-08-02 2003-07-31 Impfstoffzusammensetzung
DE20321890U Expired - Lifetime DE20321890U1 (de) 2002-08-02 2003-07-31 Impfstoffzusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE20321890U Expired - Lifetime DE20321890U1 (de) 2002-08-02 2003-07-31 Impfstoffzusammensetzung

Country Status (25)

Country Link
US (9) US20060034854A1 (cg-RX-API-DMAC7.html)
EP (11) EP2258386A3 (cg-RX-API-DMAC7.html)
JP (7) JP2006506467A (cg-RX-API-DMAC7.html)
KR (6) KR101140033B1 (cg-RX-API-DMAC7.html)
CN (2) CN1674933B (cg-RX-API-DMAC7.html)
AU (6) AU2003253375B2 (cg-RX-API-DMAC7.html)
CA (4) CA2493977A1 (cg-RX-API-DMAC7.html)
CO (3) CO5680454A2 (cg-RX-API-DMAC7.html)
CY (3) CY1114243T1 (cg-RX-API-DMAC7.html)
DE (2) DE20321889U1 (cg-RX-API-DMAC7.html)
DK (2) DK2255826T3 (cg-RX-API-DMAC7.html)
ES (3) ES2537737T3 (cg-RX-API-DMAC7.html)
HU (1) HUE029200T2 (cg-RX-API-DMAC7.html)
IL (3) IL165660A0 (cg-RX-API-DMAC7.html)
IS (3) IS7593A (cg-RX-API-DMAC7.html)
LU (1) LU92262I2 (cg-RX-API-DMAC7.html)
MX (3) MXPA05000842A (cg-RX-API-DMAC7.html)
MY (1) MY149591A (cg-RX-API-DMAC7.html)
NO (3) NO20050008L (cg-RX-API-DMAC7.html)
NZ (4) NZ537181A (cg-RX-API-DMAC7.html)
PL (5) PL375408A1 (cg-RX-API-DMAC7.html)
PT (2) PT2255826E (cg-RX-API-DMAC7.html)
SI (2) SI1524993T1 (cg-RX-API-DMAC7.html)
TW (1) TWI360424B (cg-RX-API-DMAC7.html)
WO (4) WO2004014417A2 (cg-RX-API-DMAC7.html)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261357A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US10967045B2 (en) * 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
NZ528254A (en) 1999-05-19 2005-07-29 Chiron S Combined neisserial compositions
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MXPA02007184A (es) * 2000-01-25 2004-02-26 Univ Queensland Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.
ATE352631T1 (de) 2000-02-28 2007-02-15 Novartis Vaccines & Diagnostic Heterologe expression von neisseria proteine
BRPI0112928B1 (pt) * 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DK2255826T3 (en) * 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2353608B1 (en) * 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005028665A2 (en) 2003-09-19 2005-03-31 Epitopix, Llc Campylobacter polypeptides and methods of use
PT1961426E (pt) 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
GB0323709D0 (en) * 2003-10-09 2003-11-12 Health Prot Agency Modified whole cell,cell extract and omv-based vaccines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1706481A2 (en) 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
MXPA06013093A (es) 2004-05-11 2007-08-08 Nederlanden Staat Lipo-oligo-sacarido de neisseria meningitidis igtb como adyuvante.
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428381D0 (en) * 2004-12-24 2005-02-02 Isis Innovation Vaccine
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
EP1848732B1 (en) 2005-01-21 2016-07-27 Epitopix, LLC Yersinia spp. polypeptides and methods of use
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
ATE536884T1 (de) 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7955817B2 (en) 2005-09-02 2011-06-07 Glaxosmithkline Biologicals S.A. Vaccine protection assay
EP2333549A3 (en) * 2005-09-05 2011-11-02 GlaxoSmithKline Biologicals s.a. Serum bactericidal assay for n. meningitidis specific antisera
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2632434A1 (en) * 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
ES2390291T3 (es) 2006-06-12 2012-11-08 Glaxosmithkline Biologicals S.A. Vacunas LOS L3V
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
HRP20151122T1 (hr) 2007-06-26 2015-11-20 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae
JP2010535019A (ja) * 2007-08-02 2010-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リポオリゴ糖（ｌｏｓ）生合成に関わる遺伝子の有無の決定によるナイセリア属菌株の分子タイピング
WO2009038889A1 (en) * 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
JP5380465B2 (ja) 2008-03-03 2014-01-08 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
KR101042541B1 (ko) * 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
US20110182981A1 (en) * 2008-08-25 2011-07-28 Peixuan Zhu Gonococcal vaccines
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CN101759781B (zh) * 2008-12-25 2013-04-03 上海市第六人民医院 一种细菌表层黏附蛋白及其用途
EP2382985B1 (en) 2008-12-25 2015-05-06 The Chemo-Sero-Therapeutic Research Institute Recombinant avian-infectious coryza vaccine and method for producing same
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
WO2010109325A2 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
LT2411048T (lt) 2009-03-24 2020-06-25 Glaxosmithkline Biologicals Sa Adjuvantinį meningokokinį faktorių h surišantis baltymas
WO2010130899A1 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis
CA2761916A1 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
WO2010130898A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
JP5536765B2 (ja) * 2009-05-20 2014-07-02 国立大学法人鳥取大学 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
JP2013503148A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
JP5818793B2 (ja) 2009-09-01 2015-11-18 イオン メディックス インコーポレイテッド 腸内共生細菌由来細胞外ベシクル、並びにこれを用いた疾病モデル、ワクチン、候補薬物探索方法及び診断方法
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8642733B2 (en) * 2009-11-06 2014-02-04 Children's Hospital & Research Center Oakland T-cell stimulating protein B and methods of use
CA2784580A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CA2792683A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
ES2663872T3 (es) * 2010-03-11 2018-04-17 Glaxosmithkline Biologicals S.A. Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN103097399A (zh) * 2010-03-29 2013-05-08 南加利福尼亚大学 用于去除生物膜的组合物及方法
AU2013202310C1 (en) * 2010-03-29 2017-01-05 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
AU2011299025B2 (en) 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
ES2529442T3 (es) * 2010-09-28 2015-02-20 Abera Bioscience Ab Proteína de fusión para la expresión de proteínas secretoras
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
ES2670669T3 (es) 2011-07-07 2018-05-31 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Proceso para la producción sin detergente de vesículas de membrana externa de una bacteria gram-negativa
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013113917A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
JP5698693B2 (ja) * 2012-03-13 2015-04-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
JP2015521595A (ja) 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
WO2014122232A1 (en) 2013-02-07 2014-08-14 Novartis Ag Pharmaceutical compositions comprising vesicles
WO2014138290A1 (en) * 2013-03-05 2014-09-12 Trudeau Institute, Inc. Compositions and methods for treating bacterial infections
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10392424B2 (en) 2014-02-28 2019-08-27 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
US10232029B2 (en) 2014-12-09 2019-03-19 Sanofi Pasteur Compositions comprising N. meningitidis proteins
WO2016184860A1 (en) 2015-05-18 2016-11-24 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US12365710B2 (en) 2018-10-05 2025-07-22 Research Institute At Nationwide Children's Hospital HMGB1 protein derivatives for the removal of biofilms
KR102852282B1 (ko) * 2018-11-06 2025-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202203250D0 (en) 2022-03-09 2022-04-20 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2025077793A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001468A1 (de) 1977-10-05 1979-04-18 Chemische Werke Hüls Ag Pulverförmige Überzugsmittel, Verfahren zu deren Herstellung und deren Anwendung
EP0011243A1 (de) 1978-11-11 1980-05-28 BEHRINGWERKE Aktiengesellschaft Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4365170A (en) 1979-09-21 1982-12-21 Hitachi, Ltd. Semiconductor switch
EP0161188A2 (en) 1984-05-10 1985-11-13 Merck & Co. Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
EP0208375A2 (en) 1985-07-05 1987-01-14 SCLAVO S.p.A. Glycoproteinic conjugates having trivalent immunogenic activity
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0281673A1 (en) 1986-11-18 1988-09-14 The Research Foundation Of State University Of New York Plasmid for production of membrane protein, bacterium containing same, monoclonal antibody therefore, and method for the identification of haemophilus influenzae
EP0301992A2 (en) 1987-07-30 1989-02-01 Centro Nacional De Biopreparados Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
WO1992001791A1 (de) 1990-07-26 1992-02-06 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
WO1992001460A1 (en) 1990-07-16 1992-02-06 The University Of North Carolina Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
WO1992003467A1 (en) 1990-08-23 1992-03-05 The University Of North Carolina Of Chapel Hill Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
EP0477508A1 (en) 1990-09-28 1992-04-01 American Cyanamid Company Improved oligosaccharide conjugate vaccines
WO1993003761A1 (en) 1991-08-15 1993-03-04 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)
WO1993006861A1 (fr) 1991-10-03 1993-04-15 Pasteur Merieux Serums Et Vaccins S.A. VACCIN CONTRE LES INFECTIONS A $i(NEISSERIA MENINGITIDIS)
WO1993014155A1 (en) 1992-01-13 1993-07-22 Akzo Nobel N.V. Crosslinking of rubbers with engineering plastics
WO1993014115A1 (en) 1992-01-16 1993-07-22 Massimo Porro Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
EP0586266A1 (fr) 1992-06-19 1994-03-09 Pasteur Merieux Serums Et Vaccins Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis
WO1994012641A1 (en) 1992-11-23 1994-06-09 Connaught Laboratories Limited Haemophilus outer membrane protein
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
WO1995003327A2 (en) 1993-07-26 1995-02-02 Biosynth S.R.L. Peptides for neutralizing the toxicity of lipid a
WO1995013370A1 (en) 1993-11-08 1995-05-18 Connaught Laboratories Limited Haemophilus transferrin receptor genes
WO1995017210A1 (en) 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1996005859A1 (en) 1994-08-24 1996-02-29 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO1996029412A1 (en) 1995-03-17 1996-09-26 Biochem Vaccines Inc. Proteinase k resistant surface protein of neisseria meningitidis
WO1996033739A1 (en) 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
WO1996034960A1 (en) 1995-05-01 1996-11-07 Connaught Laboratories Limited High molecular weight major outer membrane protein of moraxella
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
WO1996040929A2 (en) 1995-06-07 1996-12-19 Connaught Laboratories Limited Transferrin receptor genes
WO1997001638A1 (en) 1995-06-27 1997-01-16 Cortecs International Limited Omp26 antigen from haemophilus influenzae
WO1997009994A1 (en) 1995-09-15 1997-03-20 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
WO1997013785A1 (en) 1995-10-11 1997-04-17 Connaught Laboratories Limited Transferrin receptor protein of moraxella
WO1997032980A1 (en) 1996-03-08 1997-09-12 Connaught Laboratories Limited Transferrin receptor genes of moraxella
WO1997041151A2 (en) 1996-05-01 1997-11-06 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
WO1997041731A1 (en) 1996-05-03 1997-11-13 Antex Biologics, Inc. Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
WO1998002547A2 (fr) 1996-07-12 1998-01-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Adn et proteines ou peptides specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
EP0834568A2 (en) 1996-09-24 1998-04-08 Smithkline Beecham Corporation Novel saliva binding protein
EP0837130A2 (en) 1996-09-24 1998-04-22 Smithkline Beecham Corporation M protein analogue from Streptococcus pneumoniae
WO1998018931A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
US5804193A (en) 1991-02-15 1998-09-08 Uab Research Foundation Truncated PSPA lacking a functional cell membrane anchor region
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
WO1999006781A1 (de) 1997-07-31 1999-02-11 Wilo Gmbh Latentwärmespeicher für ein kraftfahrzeug
WO1999009176A1 (en) 1997-08-15 1999-02-25 University Of Utrecht Neisseria lactoferrin binding protein
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
WO1999031132A1 (en) 1997-12-12 1999-06-24 The University Of Queensland NOVEL SURFACE PROTEIN OF $i(NEISSERIA MENINGITIDIS)
EP0941738A1 (en) 1998-03-10 1999-09-15 American Cyanamid Company Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
WO1999051266A2 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
WO1999052947A2 (en) 1998-04-14 1999-10-21 Connaught Laboratories Limited TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA)
WO1999055873A2 (en) 1998-04-24 1999-11-04 Smithkline Beecham Biologicals S.A. Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
WO1999055872A1 (en) 1998-04-23 1999-11-04 Smithkline Beecham Biologicals S.A. Basb013 dna and proteins from neisseria meningitidis
WO1999057277A2 (en) 1998-05-06 1999-11-11 Smithkline Beecham Biologicals S.A. Basb019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO1999058683A2 (en) 1998-05-13 1999-11-18 Smithkline Beecham Biologicals S.A. BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS)
WO1999058684A2 (en) 1998-05-13 1999-11-18 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
WO1999061620A2 (en) 1998-05-26 1999-12-02 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
WO1999063093A2 (en) 1998-06-03 1999-12-09 Smithkline Beecham Biologicals S.A. Basb027 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO1999064448A2 (en) 1998-06-05 1999-12-16 Smithkline Beecham Biologicals S.A. Moraxella catarrhalis pilq proteins
WO1999064602A2 (en) 1998-06-09 1999-12-16 Smithkline Beecham Biologicals S.A. Moraxella catarrhalis polynucleotides and polypeptides
WO2000003003A2 (en) 1998-07-10 2000-01-20 The University Of Nottingham Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
EP0976402A2 (en) 1998-07-29 2000-02-02 Biosynth S.R.L. Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases
WO2000015801A1 (en) 1998-09-14 2000-03-23 Smithkline Beecham Biologicals S.A. Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses
WO2000023593A2 (en) 1998-10-16 2000-04-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Molecular pathogenicide mediated plant disease resistance
WO2000025811A2 (en) 1998-11-02 2000-05-11 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Multicomponent meningococcal vaccine
WO2000026384A1 (en) 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
WO2000071725A2 (en) 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
WO2000078968A2 (en) 1999-06-18 2000-12-28 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
WO2001009334A1 (en) 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Basb118 polypeptide and polynucleotide from moraxella catarrhalis
WO2001009350A2 (en) 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2001009329A1 (en) 1999-07-30 2001-02-08 Smithkline Beecham Biologicals S.A. Basb126 polypeptide and polynucleotide from moraxella catarrhalis
WO2001009336A1 (en) 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Basb119 polypeptide and polynucleotide from moraxella catarrhalis
WO2001009179A1 (en) 1999-07-30 2001-02-08 Smithkline Beecham Biologicals S.A. Moraxella cattarrhalis basb114 antigens and uses thereof
WO2001052885A1 (en) 2000-01-17 2001-07-26 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
US6342224B1 (en) 1997-08-22 2002-01-29 Smithkline Beecham Biologicals, S.A. Recombinant papillomavirus vaccine and method for production and treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239746A (en) * 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package
US20020146764A1 (en) * 1985-03-28 2002-10-10 Chiron Corporation Expression using fused genes providing for protein product
DE3622221A1 (de) * 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
AU1749292A (en) * 1991-03-14 1992-10-21 Imclone Systems Incorporated Recombinant hybrid porin epitopes
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
HUP9901577A3 (en) * 1995-09-18 2000-03-28 Lowell Georg H Cote St Luc Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
JP4399112B2 (ja) * 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
EP2261357A3 (en) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
GB9820002D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
JP2004511201A (ja) * 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
WO2000023595A1 (en) 1998-10-22 2000-04-27 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
ES2522667T3 (es) * 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
CN101033467A (zh) * 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB2351515B (en) 1999-06-29 2002-09-11 Pandrol Ltd Adjustable railway rail fastening assembly and methods for use therewith
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
ATE352631T1 (de) * 2000-02-28 2007-02-15 Novartis Vaccines & Diagnostic Heterologe expression von neisseria proteine
GB0007432D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
BRPI0112928B1 (pt) * 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (pt) * 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
NZ532274A (en) 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
DK2255826T3 (en) * 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
EP2353608B1 (en) * 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
PT1961426E (pt) * 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
WO2008001224A2 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis

Patent Citations (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001468A1 (de) 1977-10-05 1979-04-18 Chemische Werke Hüls Ag Pulverförmige Überzugsmittel, Verfahren zu deren Herstellung und deren Anwendung
EP0011243A1 (de) 1978-11-11 1980-05-28 BEHRINGWERKE Aktiengesellschaft Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine
US4365170A (en) 1979-09-21 1982-12-21 Hitachi, Ltd. Semiconductor switch
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0161188A2 (en) 1984-05-10 1985-11-13 Merck & Co. Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
EP0208375A2 (en) 1985-07-05 1987-01-14 SCLAVO S.p.A. Glycoproteinic conjugates having trivalent immunogenic activity
EP0281673A1 (en) 1986-11-18 1988-09-14 The Research Foundation Of State University Of New York Plasmid for production of membrane protein, bacterium containing same, monoclonal antibody therefore, and method for the identification of haemophilus influenzae
EP0301992A2 (en) 1987-07-30 1989-02-01 Centro Nacional De Biopreparados Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor
US5597572A (en) 1987-07-30 1997-01-28 Centro Nacional De Biopreparados Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
WO1992001460A1 (en) 1990-07-16 1992-02-06 The University Of North Carolina Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
WO1992001791A1 (de) 1990-07-26 1992-02-06 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
WO1992003467A1 (en) 1990-08-23 1992-03-05 The University Of North Carolina Of Chapel Hill Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
EP0477508A1 (en) 1990-09-28 1992-04-01 American Cyanamid Company Improved oligosaccharide conjugate vaccines
US5804193A (en) 1991-02-15 1998-09-08 Uab Research Foundation Truncated PSPA lacking a functional cell membrane anchor region
WO1993003761A1 (en) 1991-08-15 1993-03-04 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)
WO1993006861A1 (fr) 1991-10-03 1993-04-15 Pasteur Merieux Serums Et Vaccins S.A. VACCIN CONTRE LES INFECTIONS A $i(NEISSERIA MENINGITIDIS)
WO1993014155A1 (en) 1992-01-13 1993-07-22 Akzo Nobel N.V. Crosslinking of rubbers with engineering plastics
WO1993014115A1 (en) 1992-01-16 1993-07-22 Massimo Porro Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
EP0586266A1 (fr) 1992-06-19 1994-03-09 Pasteur Merieux Serums Et Vaccins Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
WO1994012641A1 (en) 1992-11-23 1994-06-09 Connaught Laboratories Limited Haemophilus outer membrane protein
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
US5766608A (en) 1993-05-18 1998-06-16 The Ohio State Research Foundation DNA molecules which encode the fimbrin protein of Haemophilus influenzae
WO1995003327A2 (en) 1993-07-26 1995-02-02 Biosynth S.R.L. Peptides for neutralizing the toxicity of lipid a
WO1995013370A1 (en) 1993-11-08 1995-05-18 Connaught Laboratories Limited Haemophilus transferrin receptor genes
WO1995017210A1 (en) 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1996005859A1 (en) 1994-08-24 1996-02-29 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO1996029412A1 (en) 1995-03-17 1996-09-26 Biochem Vaccines Inc. Proteinase k resistant surface protein of neisseria meningitidis
WO1996033739A1 (en) 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
WO1996034960A1 (en) 1995-05-01 1996-11-07 Connaught Laboratories Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
WO1996040929A2 (en) 1995-06-07 1996-12-19 Connaught Laboratories Limited Transferrin receptor genes
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
WO1997001638A1 (en) 1995-06-27 1997-01-16 Cortecs International Limited Omp26 antigen from haemophilus influenzae
WO1997009994A1 (en) 1995-09-15 1997-03-20 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
WO1997013785A1 (en) 1995-10-11 1997-04-17 Connaught Laboratories Limited Transferrin receptor protein of moraxella
WO1997032980A1 (en) 1996-03-08 1997-09-12 Connaught Laboratories Limited Transferrin receptor genes of moraxella
WO1997041151A2 (en) 1996-05-01 1997-11-06 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
WO1997041731A1 (en) 1996-05-03 1997-11-13 Antex Biologics, Inc. Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
US6214981B1 (en) 1996-05-03 2001-04-10 Antex Biologics Inc. Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
WO1998002547A2 (fr) 1996-07-12 1998-01-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Adn et proteines ou peptides specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
EP0837130A2 (en) 1996-09-24 1998-04-22 Smithkline Beecham Corporation M protein analogue from Streptococcus pneumoniae
EP0834568A2 (en) 1996-09-24 1998-04-08 Smithkline Beecham Corporation Novel saliva binding protein
WO1998018930A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO1998018931A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
WO1999006781A1 (de) 1997-07-31 1999-02-11 Wilo Gmbh Latentwärmespeicher für ein kraftfahrzeug
WO1999009176A1 (en) 1997-08-15 1999-02-25 University Of Utrecht Neisseria lactoferrin binding protein
US6342224B1 (en) 1997-08-22 2002-01-29 Smithkline Beecham Biologicals, S.A. Recombinant papillomavirus vaccine and method for production and treatment
WO1999031132A1 (en) 1997-12-12 1999-06-24 The University Of Queensland NOVEL SURFACE PROTEIN OF $i(NEISSERIA MENINGITIDIS)
EP0941738A1 (en) 1998-03-10 1999-09-15 American Cyanamid Company Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
WO1999051266A2 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
WO1999052947A2 (en) 1998-04-14 1999-10-21 Connaught Laboratories Limited TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA)
WO1999055872A1 (en) 1998-04-23 1999-11-04 Smithkline Beecham Biologicals S.A. Basb013 dna and proteins from neisseria meningitidis
WO1999055873A2 (en) 1998-04-24 1999-11-04 Smithkline Beecham Biologicals S.A. Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
WO1999057277A2 (en) 1998-05-06 1999-11-11 Smithkline Beecham Biologicals S.A. Basb019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO1999058683A2 (en) 1998-05-13 1999-11-18 Smithkline Beecham Biologicals S.A. BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS)
WO1999058684A2 (en) 1998-05-13 1999-11-18 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
WO1999061620A2 (en) 1998-05-26 1999-12-02 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
WO1999063093A2 (en) 1998-06-03 1999-12-09 Smithkline Beecham Biologicals S.A. Basb027 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO1999064448A2 (en) 1998-06-05 1999-12-16 Smithkline Beecham Biologicals S.A. Moraxella catarrhalis pilq proteins
WO1999064602A2 (en) 1998-06-09 1999-12-16 Smithkline Beecham Biologicals S.A. Moraxella catarrhalis polynucleotides and polypeptides
WO2000003003A2 (en) 1998-07-10 2000-01-20 The University Of Nottingham Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
EP0976402A2 (en) 1998-07-29 2000-02-02 Biosynth S.R.L. Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases
WO2000015801A1 (en) 1998-09-14 2000-03-23 Smithkline Beecham Biologicals S.A. Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses
WO2000023593A2 (en) 1998-10-16 2000-04-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Molecular pathogenicide mediated plant disease resistance
WO2000025811A2 (en) 1998-11-02 2000-05-11 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Multicomponent meningococcal vaccine
WO2000026384A1 (en) 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
WO2000071725A2 (en) 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
WO2000078968A2 (en) 1999-06-18 2000-12-28 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
WO2001009329A1 (en) 1999-07-30 2001-02-08 Smithkline Beecham Biologicals S.A. Basb126 polypeptide and polynucleotide from moraxella catarrhalis
WO2001009179A1 (en) 1999-07-30 2001-02-08 Smithkline Beecham Biologicals S.A. Moraxella cattarrhalis basb114 antigens and uses thereof
WO2001009334A1 (en) 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Basb118 polypeptide and polynucleotide from moraxella catarrhalis
WO2001009350A2 (en) 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2001009336A1 (en) 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Basb119 polypeptide and polynucleotide from moraxella catarrhalis
WO2001052885A1 (en) 2000-01-17 2001-07-26 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
WO2001055182A1 (en) 2000-01-25 2001-08-02 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA

Non-Patent Citations (93)

* Cited by examiner, † Cited by third party
Title
"The subunit and adjuvant approach" (eds Powell M. F. & Newman M. J.) (1995) Plenum Press New York
13th international Pathogeic Neisseria Conference 2002 Masignani et al., p135
13th International Pathogenic Neisseria Conference 2002
Aebi et al., Infect Immun 1997 65; 4367 bis 4377
Aho et al., 1991 Mol. Microbiol. 5: 1429-1437
Ala'Aldeen D und Cartwright K 1996, J. Infect. 33; 153-157
Annu Rev Cell Dev Biol. 16; 423-457 (2000)
Berry & Paton, Infect Immun 1996 Dec; 64 (12): 5255-62 "Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae"
Bioconjugates Techniques. Greg T. Hermanson (1996) pp 173-176
Bjune et. al., 1991, Lancet, 338; 1093-1096
Boslego J et al., Efficacy trial of a purified gonococcl pilus vaccine, in Program and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, American Society for Microbiology, 1984
Chu C. et al., Infect. Immunity, 1983, 245-256
Comanducci et al., J. Exp. Med. 2002 195; 1445-1454
Cope et al., Immun 2000 68 Infect; 4092-4101
Cope et al., Infect Immun 2001 69; 2353-2363
Cope et al., Mol Microbiol 1994 13; 863-873
Cornelissen et al., Infection and Immunity 65; 822, 1997
de la Pas, Microbiology, 141 (Pt4): 913-20, 1995
Drabick et al., (Vaccine [2000], 18: 160-172)
Du et al., Infect Immun 1998 66; 3656-3665
Fleishmann et al., Science 1995 269; 496-512
Frederikson et al., (NIPH Annals [1991], 14: 67-80)
Fredriksen et al., 1991, NIPH Ann, 14; 67-80
Frosh et al., 1990, Mol. Microbiol. 4: 1215-1218
G. Bjune et al, Lancet (1991), 338, 1093-1096
Galanos et al., 1969, Eur J Biochem 9: 245-249
Gerbase et al. 1998 Lancet 351; (Suppl 3) 2-4
Grau-Owen et al Infect Immun 1995 63; 1201-1210
Griffiss et al., Inf. Immun. 1987; 55: 1792-1800
GVG. Sierra et al., NIPH ann (1991), 14, 195-210
Harlow und Lane Antibodies; A Laboratory Manual 1988
Helminen ME, et al., (1993) Infect. Immun. 61: 2003-2010
Infect. Immun. 1996 64: 3544
Infect. Immun. 1999, 67; 3533-3541
Infection and Immunity 2002, 70 (8); 4447-4461; NMB 1029
J. Bacteriol. 181; 2895-2901 (1999)
J. Exp. Med (2002) 195: 1445
J. Exp. Med (2002) 195: 1445; NMB 1994
J. Exp. Med. 180: 2181-2190 [1994]
J. V. Staros, R. W. Wright und D. M. Swingle. Enhancement by N-hydroxysuccinimide of water - soluble carbodiimide-mediated coupling reactions. Analytical chemistry 156: 220-222 (1986)
Jennings et al., Microbiology 1999 145; 3013-3021
Jin et al., Infect Immun 1996 64; 3134-3141
Köhler und Milstein 1975 Nature 256; 495; Antibodies - a laboratory manual Harlow und Lane 1988
Lepow et al., 1986; Peltola 1998, Pediatrics 76; 91-96
M. P. Jennings et al., Microbiology 1999, 145, 3013-3021
Maciver et al., Infect Immun 1996 64; 3703-3712
Maiden et al. PNAS USA 1998, 95: 3140-5
Mathers et al., FEMS Immunol Med Microbiol 1997 19; 231-236
McChesney D et al., Infect. Immun. 36: 1006, 1982
Med Microbiol (1999) 32: 1117
Microbiology 142; 3269-3274 (1996)
Microbiology 2001, 147; 1277-1290
Milagres et al,. 1994, Infect. Immun. 62; 4419-4424
Mitchell et al., Biochim Biophys Acta 1989 Jan 23; 1007 (1): 67-72 "Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties."
Mitchell et al., Nucleic Acids Res. 1990 Jul 11; 18 (13): 4010 "Comparison of Pneumolysin genes and proteins from Streptococcus pneumoniae types 1 and 2."
Mol Microbiol 1997, 23; 737-749
Mol Microbiol 2002, 43: 931-43
Mol Microbiol. 1997, 23; 737-749
Mol. Biol. Evol. 12; 363-370, 1995
Mol. Microbiol. 1997, 23; 879-892
Myers et al., Infect Immun 1998 66; 4183-4192
Nature Biotech 20; 914-921 (2002)
Oakhill et al., Biochem J. 2002 364; 613-6
Peltola et al., 1985, Pediatrics 76; 91-96
Perkins et al., J Infect Dis. 1998, 177: 683-691
Perkins et al., J Infect Dis. 1998. 177: 683-691
Pizza et al. (2000), Science 287: 1816-1820
Plante M, J. Infect. Dis., 182: 848-55, 2000
Poolman et al., (1985 J. Med. Micro. 19: 203-209)
R. Gluck, Vaccine, 1992, 10, 915-920
Rodriguez et al., 1999, Mem Inst. Oswaldo Cruz, Rio de Janeiro 94; 433-440
Rokbi et al., FEMS Microbiol. Lett. 100; 51, 1993
Sanchez-Beato et al., FEMS Microbiol Lett 1998, 164: 207-14
Saunders et al., (Infect. Immun. [1999], 67: 113-119)
Scholtan et al., J Med Microbiol 1994, 41: 236-243
Schryvers et al., 1989, 29: 121-130
Sethi et al., Infect. Immun. 1997 65; 3666-3671
Siegel M et al., J. Infect. Dis 145: 300, 1982
Sierra et al., 1990, In Neisseria, Walter Gruyter, Berlin, m. Atchman et al., (eds) p 129-134
Sierra et al., 1991, NIPH Ann 14, 195-210
St Geme et al., Infect Immun 1998 66; 364-368
St Geme et al., J. Bacteriol. 2000 182; 6005-6013
Tappero et al., 1999, JAMA 281; 1520 bis 1527
Tettelin et al., Science 2000 287; 1809-1815
Tettelin et al., Science 287; 1809-1815 2000
Thompson et al., (1993) Infect. Immun. 61: 2906-2911
Thompson et al., (1993) J. Bacteriol. 175: 811-818
van Ulsen et al., Immunol. Med. Microbiol. 2001 32; 53-64
Velucchi et al., (1997) J Endotoxin Res 4: 1-12
Wesphal und Jann Meth. Carbo. Chem. 5; 83-91 1965
Wolff et al., Science, (1990) 247: 1465-8
Wu et al., 1987, Anal Bio Chem 160: 281-289
Zollinger et al., (J. Clin. Invest. [1979], 63: 836-848)

Also Published As

Publication number Publication date
KR20080078082A (ko) 2008-08-26
EP2258385A3 (en) 2012-01-18
PL375407A1 (en) 2005-11-28
CY1117643T1 (el) 2017-04-26
MY149591A (en) 2013-09-13
EP1524993A2 (en) 2005-04-27
EP1524990A2 (en) 2005-04-27
AU2008255270A1 (en) 2009-01-08
AU2003250204B2 (en) 2008-06-19
US20060240045A1 (en) 2006-10-26
AU2008202479A1 (en) 2008-06-26
ES2537737T3 (es) 2015-06-11
NZ587398A (en) 2012-03-30
CN1674933A (zh) 2005-09-28
CN1674933B (zh) 2012-09-26
PL399214A1 (pl) 2012-11-19
US20110033500A1 (en) 2011-02-10
SI1524993T1 (sl) 2013-07-31
JP2006500963A (ja) 2006-01-12
IS7593A (is) 2004-12-13
TW200408406A (en) 2004-06-01
US20060034854A1 (en) 2006-02-16
PL220107B1 (pl) 2015-08-31
WO2004014418A3 (en) 2004-07-22
AU2003250204B8 (en) 2008-07-10
US20120064120A1 (en) 2012-03-15
AU2003269864A1 (en) 2004-02-25
EP2481419A2 (en) 2012-08-01
CY2013036I1 (el) 2015-12-09
EP1524993B1 (en) 2013-03-06
AU2008202479C1 (en) 2014-01-16
SI2255826T1 (sl) 2016-07-29
NZ537904A (en) 2008-03-28
WO2004015099A2 (en) 2004-02-19
JP2006505628A (ja) 2006-02-16
NZ574530A (en) 2010-12-24
CA2489030A1 (en) 2004-02-19
JP2012107036A (ja) 2012-06-07
IL213264A0 (en) 2011-07-31
JP5414651B2 (ja) 2014-02-12
JP2006506467A (ja) 2006-02-23
KR20110036642A (ko) 2011-04-07
AU2003260357B2 (en) 2009-10-29
KR101139976B1 (ko) 2012-05-08
PL375382A1 (en) 2005-11-28
NO20050010L (no) 2005-02-09
PT1524993E (pt) 2013-06-12
EP2258384A2 (en) 2010-12-08
JP2006500962A (ja) 2006-01-12
EP2258385A2 (en) 2010-12-08
EP1524991A1 (en) 2005-04-27
CN1671413A (zh) 2005-09-21
NO20050421L (no) 2005-03-30
AU2008202479B2 (en) 2011-09-22
EP2255826A3 (en) 2012-03-28
CA2493124C (en) 2014-04-29
IS7658A (is) 2005-01-20
NZ537181A (en) 2007-01-26
IL166433A (en) 2011-08-31
EP1961427A3 (en) 2009-11-04
CA2493977A1 (en) 2004-02-19
US20160082097A1 (en) 2016-03-24
EP2258387A3 (en) 2011-10-19
PT2255826E (pt) 2016-06-08
IS7601A (is) 2004-12-16
KR101239242B1 (ko) 2013-03-11
US20060051379A1 (en) 2006-03-09
KR20050028051A (ko) 2005-03-21
PL375408A1 (en) 2005-11-28
DK1524993T3 (da) 2013-06-03
ES2408251T3 (es) 2013-06-19
DE20321890U1 (de) 2012-03-12
NO20050008L (no) 2005-04-28
JP5409986B2 (ja) 2014-02-05
CO5680454A2 (es) 2006-09-29
US7838014B2 (en) 2010-11-23
KR20120036996A (ko) 2012-04-18
CA2493124A1 (en) 2004-02-19
KR20050042143A (ko) 2005-05-04
WO2004014417A3 (en) 2004-07-22
PL399492A1 (pl) 2012-11-19
US20120064119A1 (en) 2012-03-15
JP2011142916A (ja) 2011-07-28
EP2481419A3 (en) 2013-04-10
EP1961427A2 (en) 2008-08-27
AU2003260357A1 (en) 2004-02-25
AU2003250204A1 (en) 2004-02-25
WO2004014418A2 (en) 2004-02-19
IL165660A0 (en) 2006-01-15
IL166433A0 (en) 2006-01-15
CO5680456A2 (es) 2006-09-29
ES2575014T3 (es) 2016-06-23
KR101140033B1 (ko) 2012-05-07
US8221770B2 (en) 2012-07-17
CY2013036I2 (el) 2015-12-09
EP2258386A3 (en) 2011-11-02
LU92262I2 (fr) 2013-09-30
KR20050039839A (ko) 2005-04-29
EP2258387A2 (en) 2010-12-08
DK2255826T3 (en) 2016-06-20
JP4740738B2 (ja) 2011-08-03
EP2258386A2 (en) 2010-12-08
TWI360424B (en) 2012-03-21
MXPA05001265A (es) 2005-04-28
WO2004014419A1 (en) 2004-02-19
US20060057160A1 (en) 2006-03-16
KR101237329B1 (ko) 2013-02-28
MXPA05001349A (es) 2005-04-28
EP2258384A3 (en) 2011-12-28
CA2493092A1 (en) 2004-02-19
US20120027800A1 (en) 2012-02-02
WO2004014417A2 (en) 2004-02-19
AU2003253375B2 (en) 2009-07-02
CY1114243T1 (el) 2015-12-09
JP2011051997A (ja) 2011-03-17
HK1077014A1 (en) 2006-02-03
AU2003253375A1 (en) 2004-02-25
EP2255826A2 (en) 2010-12-01
HUE029200T2 (en) 2017-03-28
CO5680455A2 (es) 2006-09-29
PL216662B1 (pl) 2014-04-30
EP1524992A2 (en) 2005-04-27
JP5789203B2 (ja) 2015-10-07
WO2004015099A3 (en) 2004-04-22
MXPA05000842A (es) 2005-04-28
EP1524992B1 (en) 2015-03-04
EP2255826B1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
DE20321889U1 (de) Impfstoffzusammensetzung
ZA200500927B (en) Neisserial vaccine compositions comprising a combination of antigens
HK1144913A (en) Neisseria vaccine composition
HK1144910A (en) Neisseria vaccine composition
HK1077014B (en) Neisserial vaccine compositions comprising a combination of antigens
HK1144777A (en) Neisserial vaccine compositions comprising a combination of antigens
AU2013201086A8 (en) Neisserial vaccine compositions comprising a combination of antigens
HK1115812A (en) Neisserial vaccine compositions comprising a combination of antigens
HK1144909A (en) Neisseria vaccine composition
HK1144914A (en) Neisseria vaccine composition

Legal Events

Date Code Title Description
R082 Change of representative

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER,

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUS, DE

Representative=s name: GRUENECKER PATENT- UND RECHTSANWAELTE PARTG MB, DE

R152 Utility model maintained after payment of third maintenance fee after eight years
R207 Utility model specification

Effective date: 20120503

R152 Utility model maintained after payment of third maintenance fee after eight years

Effective date: 20120426

R071 Expiry of right
R071 Expiry of right